Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, VRTX has a ... Likely for Early Price Pops." ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

VRTX currently has a PEG ratio of 1.20. Another notable valuation metric for GILD is its P/B ratio of 7.38. The P/B ratio pits a stock's market value against its book value, which is defined as ...